What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats

被引:91
作者
Ward, John W. [1 ,2 ]
Hinman, Alan R. [1 ]
机构
[1] Task Force Global Hlth, 330 W Ponce de Leon Ave, Decatur, GA 30030 USA
[2] Ctr Dis Control & Prevent, Atlanta, GA USA
关键词
Eradication; Injection Drug Use; Health Disparities; Liver Cancer; ACTING ANTIVIRAL THERAPY; INJECTION-DRUG USE; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; VIRAL-HEPATITIS; NATIONAL-HEALTH; BORN PERSONS; INFECTION; HCV; CARE;
D O I
10.1053/j.gastro.2018.10.048
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause 1.3 million deaths annually. To prevent more than 7 million deaths by 2030, the World Health Organization set goals to eliminate HBV and HCV, defined as a 90% reduction in new infections and a 65% reduction in deaths, and prevent more than 7 million related deaths by 2030. Elimination of HBV and HCV is feasible because of characteristics of the viruses, reliable diagnostic tools, and available cost-effective or cost-saving interventions. Broad implementation of infant immunization against HBV, blood safety, and infection-control programs have greatly reduced the burden of HBV and HCV infections. To achieve elimination, priorities include implementation of HBV vaccine-based strategies to prevent perinatal transmission, safe injection practices and HCV treatment for persons who inject drugs, and testing and treatment for HBV- and HCV-infected persons. With sufficient capacity, HBV and HCV elimination programs can meet their goals.
引用
收藏
页码:297 / 310
页数:14
相关论文
共 126 条
[1]   Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India [J].
Aggarwal, Rakesh ;
Chen, Qiushi ;
Goel, Amit ;
Seguy, Nicole ;
Pendse, Razia ;
Ayer, Turgay ;
Chhatwal, Jagpreet .
PLOS ONE, 2017, 12 (05)
[2]   Hepatitis B vaccine birth dose coverage correlates worldwide with rates of institutional deliveries and skilled attendance at birth [J].
Allison, Robert D. ;
Patel, Minal K. ;
Tohme, Rania A. .
VACCINE, 2017, 35 (33) :4094-4098
[3]  
American Association for the Study of Liver Diseases and the Infectious Diseases Society of America HCV Guidance Panel, HEP C GUID AASLD IDS
[4]  
[Anonymous], 2018, Wkly Epidemiol Rec, V93, P61
[5]  
[Anonymous], 2017, Wkly Epidemiol Rec, V92, P537
[6]  
[Anonymous], 2017, Wkly Epidemiol Rec, V92, P369
[7]  
[Anonymous], MATERNAL AND NEONATA
[8]  
[Anonymous], 2015, LANCET, V385, P117
[9]   Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen [J].
Aoyagi, K ;
Ohue, C ;
Iida, K ;
Kimura, T ;
Tanaka, E ;
Kiyosawa, K ;
Yagi, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (06) :1802-1808
[10]   Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness? [J].
Assefa, Yibeltal ;
Hill, Peter S. ;
Ulikpan, Anar ;
Williams, Owain D. .
GLOBALIZATION AND HEALTH, 2017, 13